Correction: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/ CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)

Davar D, Cavalcante L, Lakhani N, *et al.* Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2). *J ImmunoTherapy Cancer* 2024;12:e009474. doi: 10.1136/jitc-2024–009474

100000 10000 Davoceticept (ng/mL) Davoceticept (ng/mL) 1000 1000 1000 100 100 10 0.1/01/0 NEON-10 0.1/Q1W 0.3/Q1W NEON-2: 0.3/Q1W NEON-2: 0.3/Q1W NEON-2: 0.1/Q1W NEON-2: 0.1/Q1W 0.3/Q1W 14 21 14 21 Nominal Time (Days) Nominal Time (Days) С D 100 0.001 mg/kg 0.3 mg/kg 80 80 1.0 ma/ka % Target Saturation 0.01 ma/ka 0.1 mg/kg 3.0 mg/kg Satura 60 60 0.3 mg/kg 10 mg/kg 40 1.0 mg/kg 40-% Target 3.0 mg/kg 20 20 0 Study Day (nominal) Study Day (nominal)

In the original article, panel B of Figure 1 was a duplicate of panel A:

The correct panel has now been added to the figure:



Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2024;12:e009474. doi:10.1136/jitc-2024-009474corr1

Check for updates